In vitro activity of synthetic antimicrobial peptides against Candida

Polish Journal of Microbiology

Volumn 55, Issue 4, 2006, Pages 303-307

  Kamysz, Wojciech ^a   Nadolski, Piotr ^a   Kȩdzia, Anna ^a   Cirioni, Oscar ^b   Barchiesi, Francesco ^b   Giacometti, Andrea ^b   Scalise, Giorgio ^b   Łukasiak, Jerzy ^a   Okrój, Marcin ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Antimicrobial activity, antimicrobial peptides; Fungi

Indexed keywords

ANTIFUNGAL AGENT; AUREIN 1.2; CITROPIN 1.1; ISEGANAN; OMIGANAN; PEXIGANAN ACETATE; TEMPORIN A; UNCLASSIFIED DRUG; UPERIN 3.6;

ARTICLE; CANDIDA; DRUG SYNTHESIS; FUNGAL STRAIN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; SOLID PHASE EXTRACTION;

ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CANDIDA; CANDIDIASIS, ORAL; HUMANS; MICROBIAL SENSITIVITY TESTS; RESPIRATORY TRACT INFECTIONS;

CANDIDA; FUNGI;

EID: 33846159109     PISSN: 17331331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Barchiesi F., L.F. Di Francesco, P. Compagnucci, D. Arzeni, A. Giacometti and G. Scalise. 1998. In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J. Antimicrob. Chemother. 41: 59-65.
2. Branchini M.L., F.H. Aoki, A.L. Colombo, H. Taguchi, K. Yamamoto and M. Miyazi. 1998. Effect of antifungal agents on Candida spp. and Pichia anomala isolated from oropharyngeal candidiasis of AIDS patients in a University Hospital in Brazil. Braz. J. Infect. Dis. 2: 187-196.
3. Chen J., T.J. Falla, H. Liu, M.A. Hurst, C.A. Fujii, D.A. Mosca, J.R. Embree, D.J. Loury, P.A. Radel, C. Cheng Chang, L. Gu and J.C. Fiddes. 2000. Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analogues. Biopolymers 55: 88-98.
4. Chia B.C., J.A. Carver, T.D. Mulhern and J.H. Bowie. 1999. The solution structure of uperin 3.6, an antibiotic peptide from the granular dorsal glands of the Australian toadlet, Uperoleia mjobergii. J. Pept. Res. 54: 137-145.
5. Christensen T. 1979. Qualitative test for monitoring coupling completeness in solid phase peptide synthesis using chloranil. Acta Chem. Scand. Series B. (Org. Chem. Biochem.) 33: 763-776.
6. CLSI. 2002. Antifungal susceptibility testing of yeasts. Approved standard-second edition. Document M-27A2. Clinical and Laboratory Standards Institute, Wayne, Pa.
7. Conlon J.M., J. Kolodziejek and N. Nowotny. 2004. Antimicrobial peptides from ranid frogs: taxonomic and phylogenetic markers and a potential source of new therapeutic agents. Biochim. Biophys. Acta 1696: 1-14.
8. de Paiva Martins C.A., C.Y. Koga-Ito and A.O.C. Jorge. 2002. Presence of Staphylococcus spp. and Candida spp. in the human oral cavity. Braz. J. Microbiol. 33: 236-240.
9. Fields G.B. and R.L. Noble. 1990. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 35: 161-214.
10. Georgopapadakou N.H. 1998. Antifungals: mechanism of action and resistance, established and novel drugs. Curr. Opin. Microbiol. 1: 547-557.
11. Kamysz W. 2005. Are antimicrobial peptides an alternative for conventional antibiotics? Nucl. Med. Rev. Cent. East Eur. 8: 78-86.
12. Karabinis A., C. Hill, B. Leclercq, C. Tancrede, D. Baume and A. Andremont. 1988. Risk factors for candidemia in cancer patients: a case-control study. J. Clin. Microbiol. 26: 429-432.
13. Law D., C.B. Moore, H.M. Wardle, L.A. Ganguli, M.G. Keaney and D.W. Denning. 1994. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J. Antimicrob. Chemother. 34: 659-68.
14. Marchetti O., P. Moreillon, J.M. Entenza Vouillamoz, M.P. Glauser, J. Bille and D. Sanglard. 2003. Fungicidal synergism of fluconazole and cyclosporine in Candida albicans is not dependent on multidrug efflux transporters encoded by the CDR1, CDR2, CaMDR1, and FLU1 genes. Antimicrob. Agents Chemother. 47: 1565-1570.
15. Nierebińska E., Z. Gwieździński, S. Urbanowski and M. Pracz. 1992. Phenomenon of increased resistance of yeast-like fungi to nystatin. Wiad. Lek. (in Polish) 45: 427-429.
16. Prasad R., S.L. Panwar and M. Smriti. 2002. Drug resistance in yeasts an emerging scenario. Adv. Microb. Physiol. 46: 155-201.
17. Punzon C., S. Resino, J.M. Bellon, M. A. Munoz-Fernandez and M. Fresno. 2002. Analysis of the systemic immune response in HIV-1-infected patients suffering from opportunistic Candida infection. Eur. Cytokine Netw. 13: 215-223.
18. Rozek T., K.L. Wegener, J.H. Bowie, I.N. Olver, J.A. Carver, J.C. Wallace and M.J. Tyler. 2000. The antibiotic and anticancer active aurein peptides from the Australian Bell Frogs Litoria aurea and Litoria raniformis the solution structure of aurein 1.2. Eur. J. Biochem. 267: 5330-5341.
19. Vanden Bossche H., F. Dromer, I. Improvisi, M. Lozano-Chiu, J.H. Rex and D. Sanglard. 1998. Antifungal drug resistance in pathogenic fungi. Med. Mycol. 36: 119-128.
20. Vazquez J.A. 2003. Treatment of candidiasis in hospitalized patients. Curr. Treatm. Options Infect. Dis. 5: 495-506.
21. Wegener K.L., P.A. Wabnitz, J.A. Carver, J.H. Bowie, B.C. Chia, J.C. Wallace and M.J. Tyler. 1999. Host defence peptides from the skin glands of the Australian blue mountains tree-frog Litoria citropa. Solution structure of the antibacterial peptide citropin 1.1. Eur. J. Biochem. 265: 627-637.
22. Wong-Beringera A., J. Hindler, L. Brankovic, L. Muehlbauer and L. Steele-Moore. 2001. Clinical applicability of antifungal susceptibility testing on non-Candida albicans species in hospitalized patients. Diagn. Microbiol. Infect. Dis. 9: 025-31.
23. Zuber T.J. and K. Baddam. 2001. Superficial fungal infection of the skin. Where and how it appears help determine therapy. Postgrad. Med. 109: 117-120, 123-126, 131-132.